44,287 Shares in Novo Nordisk A/S $NVO Acquired by Sawyer & Company Inc

Sawyer & Company Inc purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 44,287 shares of the company’s stock, valued at approximately $1,679,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership purchased a new stake in Novo Nordisk A/S in the 1st quarter valued at about $287,660,000. State Street Corp raised its holdings in shares of Novo Nordisk A/S by 0.6% in the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company’s stock valued at $284,565,000 after buying an additional 32,641 shares during the period. Envestnet Asset Management Inc. raised its holdings in shares of Novo Nordisk A/S by 1.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock valued at $193,250,000 after buying an additional 71,684 shares during the period. Royal Bank of Canada lifted its stake in Novo Nordisk A/S by 3.2% during the 1st quarter. Royal Bank of Canada now owns 4,527,779 shares of the company’s stock worth $166,396,000 after acquiring an additional 141,376 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Novo Nordisk A/S by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 3,397,121 shares of the company’s stock valued at $124,844,000 after acquiring an additional 213,443 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema delivers strong weight-loss results: In a late-stage analysis, women with obesity or overweight lost an average of 25% of their body weight after 68 weeks. The result supports CagriSema as a potentially more effective successor to Wegovy and could strengthen Novo’s long-term position in the obesity-drug market. CNBC CagriSema analysis
• Positive Sentiment: Share repurchases provide support: Novo is expanding its 2026 buyback program, reportedly totaling DKK 15 billion, and has increased its treasury-share stake to about 1.2%. Buybacks can support per-share results and signal management’s confidence in the valuation. Novo Nordisk share buyback
• Neutral Sentiment: Investment outlook remains mixed: Analysts point to attractive valuation and continued investment in obesity and cardiometabolic treatments, including CagriSema regulatory submissions and a Prothena partnership, but the company’s future performance depends on commercialization, supply expansion and regulatory execution. Novo Nordisk obesity competition analysis
• Negative Sentiment: Competition and estimate pressure remain risks: Eli Lilly and Viking Therapeutics are intensifying competition in obesity drugs, while pricing, intellectual-property and regulatory concerns—including scrutiny of GLP-1-related supplements—could limit future growth. Declining earnings estimates have also tempered the positive reaction to CagriSema’s data. Novo Nordisk earnings estimates and valuation

Novo Nordisk A/S Price Performance

Shares of NYSE NVO traded down $0.07 during trading on Wednesday, hitting $39.27. 3,203,936 shares of the company were exchanged, compared to its average volume of 16,668,912. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.66. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $64.16. The company has a market cap of $175.36 billion, a price-to-earnings ratio of 9.60, a PEG ratio of 1.30 and a beta of 0.76. The firm’s fifty day moving average price is $42.36 and its 200 day moving average price is $43.99.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. The business had revenue of $11.98 billion during the quarter. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.42 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which was paid on Tuesday, August 25th. Investors of record on Monday, August 17th were issued a $0.5786 dividend. The ex-dividend date was Monday, August 17th. This represents a dividend yield of 258.0%. This is a decrease from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s payout ratio is currently 19.80%.

Analysts Set New Price Targets

Several analysts have recently issued reports on NVO shares. Barclays reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 7th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, September 29th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. UBS Group restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 21st. Finally, Cfra lowered shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 target price on the stock. in a research report on Tuesday, September 22nd. Five research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $59.44.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.